Document Detail

IL-1β receptor antagonist reduces inflammation in hemodialysis patients.
MedLine Citation:
PMID:  21310819     Owner:  NLM     Status:  MEDLINE    
Chronic inflammation is highly prevalent in maintenance hemodialysis (MHD) patients and associates with increased mortality. IL-1β, a pro-inflammatory cytokine, is elevated in MHD patients. A balance between IL-1β and its naturally occurring antagonist may determine the inflammatory response and its consequences in this population. We performed a pilot randomized placebo-controlled trial to evaluate the efficacy of the administration of recombinant human IL-1 receptor antagonist (IL-1ra) on biomarkers of inflammation and nutrition in MHD patients with three consecutive high sensitivity C-reactive protein (hsCRP) measurements >5 mg/L. We randomly assigned 22 patients to placebo or IL-1ra (1:1) for 4 weeks; 14 completed the trial. Patients in the IL-1ra arm had a 53% reduction in mean hsCRP compared with 1% in the placebo arm (P = 0.008), a 40% reduction in mean IL-6 levels compared with a 20% increase in the placebo arm (P = 0.03), and a 23% increase in mean prealbumin compared with 6% in the placebo arm (P = NS). In conclusion, the administration of IL-1ra in MHD patients can lower biomarkers of inflammation. Whether IL-1ra administration improves survival in this population requires additional long-term studies.
Adriana M Hung; Charles D Ellis; Ayumi Shintani; Cindy Booker; T Alp Ikizler
Related Documents :
21546409 - Efficacy of halofuginone lactate in the prevention of cryptosporidiosis in dairy calves.
17609639 - How well does "evidence-based" medicine help neurologists care for individual patients?
21334859 - Pregabalin for the discontinuation of long-term benzodiazepines use: an assessment of i...
21537209 - The systemic mediator-associated response test identifies patients in failed sepsis cli...
11404199 - Management of warts and molluscum in adolescents.
21553579 - Correlates of depression among older kurdish refugees.
23797999 - Clinical efficacy of bg-12 (dimethyl fumarate) in patients with relapsing-remitting mul...
17971629 - Development of a conversion factor to facilitate comparison of national institute of he...
11096719 - Complex partial seizures in adults.
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.     Date:  2011-02-10
Journal Detail:
Title:  Journal of the American Society of Nephrology : JASN     Volume:  22     ISSN:  1533-3450     ISO Abbreviation:  J. Am. Soc. Nephrol.     Publication Date:  2011 Mar 
Date Detail:
Created Date:  2011-03-04     Completed Date:  2011-06-16     Revised Date:  2013-06-30    
Medline Journal Info:
Nlm Unique ID:  9013836     Medline TA:  J Am Soc Nephrol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  437-42     Citation Subset:  IM    
Division of Nephrology, Vanderbilt University Medical Center, 1161 21st Avenue South & Garland, Nashville, TN 37232-2372, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Biological Markers / blood
C-Reactive Protein / metabolism
Chronic Disease
Double-Blind Method
Inflammation / blood,  etiology,  prevention & control*
Interleukin 1 Receptor Antagonist Protein / therapeutic use*
Interleukin-1beta / blood
Interleukin-6 / blood
Kidney Diseases / blood,  complications,  therapy*
Middle Aged
Pilot Projects
Receptors, Interleukin-1 / antagonists & inhibitors*
Renal Dialysis*
Treatment Outcome
Grant Support
Reg. No./Substance:
0/Biological Markers; 0/Interleukin 1 Receptor Antagonist Protein; 0/Interleukin-1beta; 0/Interleukin-6; 0/Receptors, Interleukin-1; 9007-41-4/C-Reactive Protein

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Renal Dysfunction Associated with Intra-abdominal Hypertension and the Abdominal Compartment Syndrom...
Next Document:  Altered dynamics and differential infection profiles of lymphoid and myeloid cell subsets during acu...